Every Form 4 that Cytokinetics Inc. (CYTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYTK filings page.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On May 1, 2026, he exercised a non-qualified stock option covering 15,857 shares of common stock at $37.63 per share and sold 15,857 shares of common stock in an open-market transaction at $65.00 per share.
Following these transactions, Callos directly held 58,555 shares of Cytokinetics common stock. The exercised option had originally been scheduled to vest in equal monthly installments over four years until fully vested.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised options to acquire 15,000 shares of common stock at $23.26 per share and sold 15,000 shares in an open-market transaction at an average price of $63.26 per share.
After these transactions, Callos directly holds 58,555 shares of Cytokinetics common stock and 54,000 non-qualified stock options. The remaining options vest over four years from the grant date, with one quarter vesting after one year and the rest vesting monthly over the following 36 months, subject to continued employment.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share. The transaction took place on April 29, 2026 and is classified as a non-derivative sale.
After this sale, Blum directly holds 407,830 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised options and sold shares of company stock. He exercised non-qualified stock options for 3,500 shares of Common Stock at $7.80 per share, then completed an open-market sale of 3,500 Common Stock shares at $65.69 per share on the same date. Following these transactions, he directly holds 153,902 shares of Common Stock.
CYTOKINETICS INC director Nancy Wysenski received a grant of 95 shares of Common Stock valued at $65.37 per share. The award was made as part of the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this compensation-related acquisition, she directly owns 31,066 shares of Common Stock.
Cytokinetics director Wendell Wierenga received a stock grant of 95 shares of Common Stock as part of the company’s Director Equity in Lieu of Cash Retainer Program. The shares are fully vested, meaning they are not subject to additional service conditions.
Following this equity award, Wierenga directly holds a total of 32,637 shares of Cytokinetics Common Stock. This Form 4 reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The shares were granted under the Director Equity in Lieu of Cash Retainer Program at a reference price of $65.37 per share and are fully vested. Following this compensation-related award, he directly holds 10,365 shares of Cytokinetics common stock.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director John T. Henderson received 325 shares of Common Stock as equity compensation instead of a cash retainer. The award was granted under the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this grant, he directly holds 75,237 shares, with an additional 83 shares held indirectly through his spouse.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Robert Arthur Harrington received a grant of 191 shares of Common Stock as equity compensation. The shares were granted under a Director Equity in Lieu of Cash Retainer Program and are fully vested, meaning he owns them outright. Following this award, he directly holds 18,930 shares of CYTOKINETICS INC common stock.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director James M. Daly received 191 shares of common stock as a fully vested equity award under the Director Equity in Lieu of Cash Retainer Program. The shares were valued at $65.37 each on the grant date. After this award, Daly directly holds 388 CYTK common shares.
CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of common stock. He sold 7,500 shares of Cytokinetics common stock at $65.38 per share on April 15, 2026.
After this transaction, Blum directly owns 415,330 shares of Cytokinetics common stock. He also has indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics EVP of Research & Development Fady Malik exercised stock options and sold shares on April 7, 2026. He exercised options covering 3,500 shares at $7.80 and 1,000 shares at $10.60 per share, then sold a total of 4,500 common shares in open-market transactions.
The sales involved 3,500 shares at $65.21 and 1,000 shares at $64.75 per share. After these exercise-and-sell transactions, he directly holds 153,902 shares of Cytokinetics common stock. This filing reflects a routine combination of option exercises and partial share sales by a senior executive.
Cytokinetics Inc President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $66.63 per share. Following the sale, he directly holds 422,830 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 3,639 shares of Common Stock in an open-market transaction at $65.00 per share. The sale occurred on March 31, 2026. After this transaction, he continues to hold 66,004 shares of Cytokinetics Common Stock directly.
Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share. According to the footnote, this was a company-compelled sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting, rather than a discretionary sale. After the transaction, Lee directly holds 87,127 shares, indicating he retains a substantial equity position.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.
These sell‑to‑cover transactions were executed in two tranches and are tied to compensation, rather than discretionary trading. Following the sales, Callos directly holds 71,573 Cytokinetics shares, maintaining a substantial equity stake in the company.
CYTOKINETICS INC EVP of R&D Fady Malik reported tax-related stock sales. On the reported date, he sold a total of 12,033 shares of common stock in open-market transactions at $62.15 per share.
Footnotes state these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, indicating they were driven by taxes rather than discretionary selling. After the transactions, he continued to hold 153,902 shares directly.
Cytokinetics Inc. President & CEO Robert I. Blum reported an open-market sale of 36,601 shares of common stock at $62.15 per share. According to the footnotes, these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, rather than discretionary sales.
After these transactions, Blum holds 430,330 shares of common stock directly. In addition, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,930 shares of Common Stock in an open-market transaction at $62.07 per share. The sale was reported as a direct ownership transaction. After this trade, Callos continues to hold 78,185 shares of Cytokinetics common stock.
Cytokinetics President & CEO Robert I. Blum reported equity awards and updated holdings. On March 15, 2026, he received an annual grant of 75,258 shares of common stock as restricted stock units that convert 1:1 into common shares.
These RSUs vest 40% on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third, subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He was also granted 1,665 incentive stock options and 111,864 non-qualified stock options at an exercise price of $60.06 per share, vesting in 48 equal monthly installments and expiring on March 14, 2036. Following these awards, his direct common stock holdings total 466,931 shares. Indirectly, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics executive Andrew Callos received new equity awards as part of his compensation. On March 15, 2026, he was granted 1,665 incentive stock options and 29,480 non-qualified stock options to buy common stock at an exercise price of $60.06 per share, expiring on March 14, 2036.
These stock options vest in 48 equal monthly installments, subject to his continued employment and the company’s Amended and Restated 2004 Equity Incentive Plan. He also received 20,646 restricted stock units as an annual equity award and 13,320 restricted stock units as a special supplemental award, which convert 1:1 into common shares as they vest over one to three years.
Following these awards, Callos directly holds 81,824 shares of common stock. All transactions are coded as awards or acquisitions, with no open-market purchases or sales reported in this filing.
Cytokinetics Inc. reported that Chief Legal & Admin Officer Jeffrey Hessekiel received new equity awards. On March 15, 2026, he was granted 8,325 incentive stock options and 22,820 non-qualified stock options, each with an exercise price of $60.06 per share and expiring on March 14, 2036. These stock options vest in 48 equal monthly installments, conditioned on his continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He also received an annual equity award of 20,646 shares of common stock in the form of restricted stock units that convert 1-for-1 into common shares and vest 40% on each of the first and second anniversaries of the grant date and 20% on the third anniversary, also subject to continued employment. Following these awards, he directly holds 107,943 shares of Cytokinetics common stock.
Cytokinetics EVP and CFO Sung Lee received new equity awards. On 2026-03-15, Lee was granted 20,646 shares of Common Stock as an annual restricted stock unit award, increasing his direct holdings to 92,062 shares. He also received incentive and non-qualified stock options on 1,665 and 29,480 shares at an exercise price of $60.0600, vesting over four years.
Cytokinetics EVP of Research & Development Fady Ibraham Malik received new equity awards. On March 15, 2026, he was granted 27,306 shares of common stock as restricted stock units, increasing his direct common share holdings to 165,935.
He was also granted incentive stock options on 1,665 shares and non-qualified stock options on 39,527 shares, each with a $60.06 exercise price and expiring on March 14, 2036. The RSUs vest 40% after one year, 40% after two years, and 20% after three years, while the options vest in 48 equal monthly installments, all subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,709 shares of Common Stock in an open-market transaction at $61.03 per share. After this sale, he directly holds 46,149 shares, so the transaction represents a relatively small portion of his total reported holdings.
CYTOKINETICS INC executive Andrew Callos reported a small, tax-related stock sale. On the vesting of restricted stock units, he sold 2,582 shares of common stock on March 9, 2026 at $60.72 per share to satisfy company tax withholding obligations, and now directly holds 47,858 shares.
Cytokinetics EVP Research & Development Fady Ibraham Malik reported a small tax-related share sale. He sold 2,907 shares of Common Stock on March 9, 2026 in an open-market transaction at $60.72 per share.
According to the footnote, this was a sell-to-cover transaction to satisfy company tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale. After the transaction, he directly holds 138,629 shares of Cytokinetics common stock.
Cytokinetics President & CEO Robert I. Blum reported a small share sale primarily to cover tax obligations. On 2026-03-09, he sold 7,931 shares of common stock at $60.72 per share, described as a sell-to-cover transaction for company tax withholding on vested RSUs.
After this transaction, Blum directly holds 391,673 common shares, indicating the sale represents a minor portion of his direct stake. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC executive Andrew Callos, EVP and Chief Commercial Officer, reported multiple stock option exercises and related share sales. On March 5, 2026, he exercised two non-qualified stock options covering 11,000 and 15,000 shares, converting them into common stock through derivative exercises.
He then completed two open-market sales of common stock totaling 26,000 shares, with 15,000 shares sold at $61.87 per share and 11,000 shares sold at $61.88 per share. After these transactions, he held 50,440 shares of common stock directly. The reported stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued employment.
Cytokinetics Inc director Lynne Parshall reported an open-market sale of common stock. On March 2, 2026, she sold 5,000 shares at an average price of $61.21 per share. After this transaction, she directly owns 17,933 shares of Cytokinetics common stock.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and related share sale. On March 2, 2026, he exercised an Incentive Stock Option for 886 shares, converting it into 886 shares of common stock at $37.63 per share. The same day, he then sold 886 shares of common stock at $61.62 per share in an open-market transaction. After these transactions, he held 50,440 shares of Cytokinetics common stock directly. The option grant referenced in the filing vests in equal monthly installments over four years from its grant date.
Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.
That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and matching share sale in company common stock. On February 2, 2026, he exercised 886 shares under an incentive stock option at $37.63 per share.
The same day, he sold 886 common shares at $62.10 per share. After these transactions, Callos directly held 50,440 common shares and 886 incentive stock options. The option grant vests in equal monthly installments over four years from the grant date.
Cytokinetics director James M. Daly reported receiving company stock as board compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to members of the board of directors. Following this transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership.
Cytokinetics director Nancy Wysenski reported receiving additional company stock as part of her board compensation. On 01/15/2026, she acquired 98 shares of common stock at a reported price of $63.44 per share, taken in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, she beneficially owned 30,971 shares of Cytokinetics common stock, held directly.
Cytokinetics director Wendell Wierenga reported a routine equity compensation transaction. On January 15, 2026, he acquired 98 shares of Cytokinetics common stock at $63.44 per share. According to the footnote, these fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this grant, he beneficially owns 32,542 common shares directly.
Cytokinetics director Edward M. Kaye, M.D. reported receiving additional company stock as part of his board compensation. On 01/15/2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. According to the filing, these were fully vested shares issued in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, Dr. Kaye directly owned 10,174 shares of Cytokinetics common stock.
Cytokinetics director John T. Henderson reported receiving 334 shares of Cytokinetics common stock on 01/15/2026 at a value of $63.44 per share. These fully vested shares were issued in lieu of a cash retainer under the company’s Equity in Lieu of Cash Retainer Option available to members of the Board of Directors.
After this award, Henderson beneficially owned 74,912 shares of Cytokinetics common stock directly, and an additional 83 shares indirectly through his spouse. This filing reflects routine equity compensation for board service rather than an open-market share purchase.
Cytokinetics director Robert Arthur Harrington reported receiving additional company stock as compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These were fully vested shares received in lieu of a cash retainer under an equity compensation option available to members of the Board of Directors.
Following this transaction, Harrington beneficially owned 18,739 shares of Cytokinetics common stock in direct ownership. The filing reflects routine director compensation paid in stock rather than cash, with no sales reported.
Cytokinetics executive Dr. Malik, EVP of Research & Development, reported insider transactions dated 12/16/2025. The disclosure shows an exercise of 2,200 incentive stock options at $10.60 per share, creating 2,200 shares of common stock, followed by a same-day sale of 2,200 common shares at $61.24 per share. After these transactions, Dr. Malik directly beneficially owns 138,552 shares of Cytokinetics common stock.
Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025. The filing shows the disposition of 5,930 shares of common stock at a price of $65.02 per share, recorded under transaction code F.
After this transaction, the reporting person directly beneficially owns 350,202 shares of Cytokinetics common stock. In addition, the filing notes indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS, INC. (CYTK) reported an insider stock sale by a director. On 11/19/2025, the director sold 5,000 shares of common stock in an open market transaction coded as a sale at a price of $64.73 per share. After this transaction, the director beneficially owns 22,933 shares of CYTOKINETICS common stock in direct ownership. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Cytokinetics (CYTK) Form 4 discloses an insider stock option exercise and sale by an executive. The company’s Executive Vice President of Research & Development reported exercising stock options for 2,200 shares of common stock at a price of $10.60 per share on 11/18/2025, then selling 2,200 shares of common stock the same day at a price of $66.45 per share.
After these transactions, the executive directly beneficially owned 140,610 shares of Cytokinetics common stock and held 4,400 derivative securities (stock options) following the reported activity. The filing is made by a single reporting person and is a routine disclosure of insider equity transactions.
Cytokinetics, Inc. (CYTK) reported an equity award to its Chief Legal & Admin Officer, Mr. Hessekiel. On 11/14/2025, he received an initial new hire grant of 87,297 restricted stock units (RSUs) of common stock at a price of $0 per share, all held as direct ownership after the transaction.
The RSUs convert into common stock on a 1:1 basis as they vest. The vesting schedule is staggered over three years: 40% of the RSUs vest one year from the grant date, another 40% vest two years from the grant date, and the remaining 20% vest three years from the grant date, in each case conditioned on his continued employment with Cytokinetics.
Cytokinetics (CYTK) filed a Form 4 reporting insider activity. On 11/11/2025, a director exercised 5,175 stock options at $9.66 per share (code M), then sold 5,175 shares at $65.08 (code S). After these transactions, the director beneficially owned 9,977 shares, held directly.
The exercised options were non-qualified options originally exercisable beginning 08/01/2016 and expiring 07/01/2026, covering 5,175 underlying common shares.
Cytokinetics (CYTK) reported an insider transaction on a Form 4. The company’s President & CEO and Director reported a bona fide gift (Code G) of 2,000 shares of common stock on 11/05/2025 at a price of $0.
Following the transaction, the reporting person beneficially owns 356,108 shares directly, plus 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics (CYTK) reported an insider transaction by its EVP, Research & Development. On 11/04/2025, the officer exercised 2,295 incentive stock options at $10.60 per share (code M) and sold 2,295 common shares at $59.55 (code S). Following these transactions, the officer held 140,610 common shares directly and retained 6,600 derivative securities (options).
Cytokinetics (CYTK) disclosed an insider transaction via Form 4. President & CEO and Director Mr. Blum reported a sale of 5,000 shares of common stock on 10/30/2025 at a price of $62.86 per share (transaction code S). Following the sale, he beneficially owns 358,108 shares directly.
He also reports indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. No derivative securities were reported in this filing.